On March 13, 2023, Vivasure Medical Limited closed the transaction. The company has received 52 million in the transaction. The company has received its second and final tranche of 30 million from new investor, Haemonetics Corporation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.3 USD | +1.53% | +14.72% | -41.95% |
05-13 | Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q1 Revenue $620,000 | MT |
05-13 | Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
88.34 USD | -0.34% | -6.81% | 4.51B | ||
5.3 USD | +1.53% | +14.72% | 187M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.95% | 187M | |
+10.03% | 223B | |
+13.59% | 194B | |
+20.01% | 141B | |
+30.83% | 109B | |
+2.05% | 64.85B | |
+15.38% | 52.7B | |
+3.96% | 51.77B | |
+8.37% | 44.12B | |
+3.27% | 36.21B |
- Stock Market
- Equities
- OBIO Stock
- News Orchestra BioMed Holdings, Inc.
- Vivasure Medical Limited announced that it has received €52 million in funding from Fountain Healthcare Partners Ltd., Orchestra BioMed Holdings, Inc., EQT Life Sciences, Panakès Partners SGR SpA, Evonik Venture Capital GmbH, Haemonetics Corporation, and other investors